New drug lead candidates to treat diabetic kidney disease
Bidragets beskrivning
Up to 50% of people with diabetes develop diabetic kidney disease, which may progress to end-stage kidney disease requiring dialysis or kidney transplant. This lowers the quality of life and increases mortality. Current medications in use can't stop the development and progression of diabetic kidney disease. Insulin resistance (inability of cells to respond to insulin) is a central risk factor for diabetic kidney disease. We have created a library of small compounds, which sensitize muscle cells to insulin and enhance glucose uptake, and also protect kidney cells from death in cell culture. The aim of our project is to study whether the compounds lower insulin resistance and improve kidney function in a diabetic mouse model. In future, the compounds can be utilized to design new insulin sensitizing and blood glucose lowering medications, which prevent the development of diabetic kidney disease.
Visa merStartår
2025
Slutår
2026
Beviljade finansiering
Finansiär
Finlands Akademi
Typ av finansiering
Akademiprojekt med särskild inriktning
Beslutfattare
Suomen akatemian muu päättäjä
28.11.2024
28.11.2024
Övriga uppgifter
Finansieringsbeslutets nummer
365347
Vetenskapsområden
Biomedicinska vetenskaper
Forskningsområden
Biolääketieteet